MacroGenics (MGNX) Corporate presentation summary

Platform technologies and pipeline

• Proprietary DART and TRIDENT platforms support a broad pipeline of antibody-based cancer therapeutics.

• Three FDA-approved therapeutics and four clinical-stage candidates are highlighted.

• Pipeline includes ADCs, dual checkpoint inhibitors, and T-cell engagers, with significant rights retained.

• Multiple programs have exclusive options or partnerships, notably with Gilead.

Lead clinical programs and development updates

• MGC026, a B7-H3 ADC, shows encouraging safety and anti-tumor activity across several cancers, with no ILD or ocular toxicity observed.

• MGC028 targets ADAM9 and is in Phase 1, with broad preclinical activity and a clinical update expected late 2026.

• MGC030 targets an undisclosed antigen, with IND cleared and dose escalation to begin in 3Q2026.

• Lorigerlimab, a dual PD-1/CTLA-4 DART molecule, is advancing in clear cell gynecologic cancer with interim data to be presented at ESMO 2026.

• MGD024, a CD123×CD3 DART molecule, is in Phase 1 for hematologic malignancies and subject to a Gilead option.

Market opportunities and unmet needs

• Significant unmet need exists in SCCHN, with poor response rates to current therapies and no preferred regimens in later lines.

• Clear cell gynecologic cancers are chemo-resistant with limited ongoing therapeutic development.

• ADCs and checkpoint inhibitors show potential for enhanced anti-tumor activity in combination.